Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections

Journal of Orthopaedic Research

Volumn 36, Issue 1, 2018, Pages 22-32

  Li, Bingyun ^a,b   Webster, Thomas J ^c,d  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c Northeastern University   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

antibiotic alternative; antibiotic resistance; infection; multidrug resistance; orthopedic implant; S. aureus

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIOPHAGE; BIOFILM; CLINICAL OUTCOME; DISEASE ASSOCIATION; GENE SEQUENCE; HEALTH STATUS; HOSPITALIZATION; HUMAN; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; PLASMID; PREVALENCE; PRIORITY JOURNAL; PROSTHESIS INFECTION; TREATMENT FAILURE; INFECTION; ORTHOPEDIC SURGERY;

DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; ORTHOPEDIC PROCEDURES; PROSTHESIS-RELATED INFECTIONS;

EID: 85042931333     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.23656     Document Type: Article

References (68)

1. Hirsch EF. 2008. The treatment of infected wounds, Alexis Carrel's contribution to the care of wounded soldiers during World War I. J Trauma 64:S209–S210.
2. Boucher HW, Talbot GH, Benjamin DK Jr., et al. 2013. 10 × ′20 progress–development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685–1694.
3. DiMasi JA, Grabowski HG, Hansen RW. 2016. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Economics 47:20–33.
4. O'Connell KM, Hodgkinson JT, Sore HF, et al. 2013. Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials. Angew Chem Int Ed Engl 52:10706–10733.
5. Boucher HW, Talbot GH, Bradley JS, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12.
6. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013 (http://www.cdc.gov/drugresistance/threat-report-2013/; accessed on January 16, 2017).
7. Friedman ND, Temkin E, Carmeli Y. 2016. The negative impact of antibiotic resistance. Clin Microbiol Infect 22:416–422.
8. World Health Organization. 2014 Global Report on Antimicrobial Resistance, 2014 (http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1; accessed on January 16, 2017).
9. Cosgrove SE, Kaye KS, Eliopoulous GM, et al. 2002. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 162:185–190.
10. Borer A, Saidel-Odes L, Riesenberg K, et al. 2009. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 30:972–976.
11. OECD. Antimicrobial resistance in G7 countries and beyond: economic issues, policies and options for action. 2015. Available at: http://www.oecd.org/els/health-systems/antimicrobial-resistance.htm
12. Roberts RR, Hota B, Ahmad I, et al. 2009. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 49:1175–1184.
13. Report to the President on Combating Antibiotic Resistance, Executive Office of the President, President's Council of Advisors on Science and Technology, United States, September 2014 (http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf; accessed on January 16, 2017).
14. Blair JMA, Webber MA, Baylay AJ, et al. 2015. Molecular mechanisms of antibiotic resistance. Nat Rev Micro 13:42–51.
15. Walker DF, T. Annual report of the chief medical officer: volume two, 2011: infections and the rise of antimicrobial resistance (Department of Health, 2011).
16. Bengtsson B, Greko C. 2014. Antibiotic resistance-consequences for animal health, welfare, and food production. Upsala J Med Sci 119:96–102.
17. About antimicrobial resistance. Centers for Disease Control and Prevention. https://www.cdc.gov/drugresistance/about.html. Accessed on May 22, 2017.
18. Lin J, Nishino K, Roberts MC, et al. 2015. Mechanisms of antibiotic resistance. Front Microbiol 6:34.
19. Chellat MF, Raguz L, Riedl R. 2016. Targeting antibiotic resistance. Angew Chem Int Ed Engl 55:6600–6626.
20. Fair RJ, Tor Y. 2014. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem 6:25–64.
21. Liu B, Pop M. 2009. ARDB-antibiotic resistance genes database. Nucleic Acids Res 37:D443–D447.
22. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318–1322.
23. Arciola CR, Campoccia D, Gamberini S, et al. 2005. Antibiotic resistance in exopolysaccharide-forming Staphylococcus epidermidis clinical isolates from orthopaedic implant infections. Biomaterials 26:6530–6535.
24. Doyle MP, Busta FF, Cords B, et al. 2006. Antimicrobial resistance: implications for the food system. Compr Rev Food Sci Food Saf 5:7.
25. Allen HK, Donato J, Wang HH, et al. 2010. Call of the wild: antibiotic resistance genes in natural environments. Nat Rev Microbiol 8:251–259.
26. Szczepanowski R, Linke B, Krahn I, et al. 2009. Detection of 140 clinically relevant antibiotic-resistance genes in the plasmid metagenome of wastewater treatment plant bacteria showing reduced susceptibility to selected antibiotics. Microbiology 155:2306–2319.
27. Subirats J, Sanchez-Melsio A, Borrego CM, et al. 2016. Metagenomic analysis reveals that bacteriophages are reservoirs of antibiotic resistance genes. Int J Antimicrob Agents 48:163–167.
28. Bartoloni A, Pallecchi L, Rodriguez H, et al. 2009. Antibiotic resistance in a very remote Amazonas community. Int J Antimicrob Agents 33:125–129.
29. Pallecchi L, Bartoloni A, Paradisi F, et al. 2008. Antibiotic resistance in the absence of antimicrobial use: mechanisms and implications. Expert Rev Anti-Infect Ther 6:725–732.
30. D/'Costa VM, King CE, Kalan L, et al. 2011. Antibiotic resistance is ancient. Nature 477:457–461.
31. Cherifi S, Byl B, Deplano A, et al. 2013. Comparative epidemiology of Staphylococcus epidermidis isolates from patients with catheter-related bacteremia and from healthy volunteers. J Clin Microbiol 51:1541–1547.
32. Arciola CR, Campoccia D, An YH, et al. 2006. Prevalence and antibiotic resistance of 15 minor staphylococcal species colonizing dic implants. Int J Artif Organs 29:395–401.
33. Martinez-Pastor JC, Vilchez F, Pitart C, et al. 2010. Antibiotic resistance in orthopaedic surgery: acute knee prosthetic joint infections due to extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae. Eur J Clin Microbiol 29:1039–1041.
34. Ravi S, Zhu M, Luey C, et al. 2016. Antibiotic resistance in early periprosthetic joint infection. ANZ J Surg 86:1014–1018.
35. Campoccia D, Montanaro L, Arciola CR. 2006. The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomaterials 27:2331–2339.
36. Malhas AM, Lawton R, Reidy M, et al. 2015. Causative organisms in revision total hip & knee arthroplasty for infection: increasing multi-antibiotic resistance in coagulase-negative Staphylococcus and the implications for antibiotic prophylaxis. Surgeon 13:250–255.
37. Bogut A, Niedzwiadek J, Strzelec-Nowak D, et al. 2014. Infectious prosthetic hip joint loosening: bacterial species involved in its aetiology and their antibiotic resistance profiles against antibiotics recommended for the therapy of implant-associated infections. New Microbiol 37:209–218.
38. Campoccia D, Montanaro L, Baldassarri L, et al. 2005. Antibiotic resistance in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates from implant orthopedic infections. Int J Artif Organs 28:1186–1191.
39. Morgenstern M, Erichsen C, von Ruden C, et al. 2016. Staphylococcal orthopaedic device-related infections in older patients. Injury 47:1427–1434.
40. Salgado CD, Dash S, Cantey JR, et al. 2007. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin Orthop Rel Res 461:48–53.
41. Kilgus DJ, Howe DJ, Strang A. 2002. Results of periprosthetic hip and knee infections caused by resistant bacteria. Clin Orthop Rel Res 404:116–124.
42. Joshy S, Gogi N, Thomas B, et al. 2007. Delayed onset of deep infection after total knee arthroplasty: comparison based on the infecting organism. J Orthop Surg 15:154–158.
43. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. 2004. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 23:701–706.
44. Kini AR, Shetty V, Kumar AM, et al. 2013. Community-associated, methicillin-susceptible, and methicillin-resistant Staphylococcus aureus bone and joint infections in children: experience from India. J Pediatr Orthop Part B 22:158–166.
45. Inoue S, Moriyama T, Horinouchi Y, et al. 2013. Comparison of clinical features and outcomes of staphylococcus aureus vertebral osteomyelitis caused by methicillin-resistant and methicillin-sensitive strains. SpringerPlus 2:283.
46. Lora-Tamayo J, Murillo O, Iribarren JA, et al. 2013. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis 56:182–194.
47. Senneville E, Joulie D, Legout L, et al. 2011. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 53:334–340.
48. Ryu DJ, Kang JS, Moon KH, et al. 2014. Clinical characteristics of methicillin-resistant Staphylococcus aureus infection for chronic periprosthetic hip and knee infection. Hip Pelvis 26:235–242.
49. O'Neill J. 2016. Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance.
50. Goossens H, Ferech M, Vander Stichele R, et al. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579–587.
51. Perlroth J, Kuo M, Tan J, et al. 2008. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 168:805–819.
52. Parvizi J, Shohat N, Gehrke T. 2017. Prevention of periprosthetic joint infection: new guidelines. Bone Joint J 99-b:3–10.
53. http://www.who.int/gpsc/ssi-prevention-guidelines/en/. Accessed on April 2, 2017.
54. https://www.cdc.gov/hicpac/SSI/001_SSI.html. Accessed on April 2, 2017.
55. O'Neill J. 2015. Rapid diagnostics: stopping unnecessary use of antibiotics. Review on Antimicrobial Resistance.
56. Li B, Jiang B, Boyce BM, et al. 2009. Multilayer polypeptide nanoscale coatings incorporating IL-12 for the prevention of biomedical device-associated infections. Biomaterials 30:2552–2558.
57. Li B, Jiang B, Dietz MJ, et al. 2010. Evaluation of local MCP-1 and IL-12 nanocoatings for infection prevention in open fractures. J Orthop Res 28:48–54.
58. Li B, McKeague AL. 2011. Emerging ideas: interleukin-12 nanocoatings prevent open fracture-associated infections. Clin Orthop Rel Res 469:3262–3265.
59. Li H, Hamza T, Tidwell JE, et al. 2013. Unique antimicrobial effects of platelet-rich plasma and its efficacy as a prophylaxis to prevent implant-associated spinal infection. Adv Healthc Mater 2:1277–1284.
60. Finlay BB, Hancock REW. 2004. Can innate immunity be enhanced to treat microbial infections? Nat Rev Micro 2:497–504.
61. Boyce BM, Lindsey BA, Clovis NB, et al. 2012. Additive effects of exogenous IL-12 supplementation and antibiotic treatment in infection prophylaxis. J Orthop Res 30:196–202.
62. Webster TJ, Patel AA, Rahaman MN, et al. 2012. Anti-infective and osteointegration properties of silicon nitride, poly(ether ether ketone), and titanium implants. Acta biomater 8:4447–4454.
63. Taylor EN, Webster TJ. 2010. Multifunctional magnetic nanoparticles for orthopedic and biofilm infections. Int J Nanotechn 8:21–35.
64. Taylor E, Webster TJ. 2011. Reducing infections through nanotechnology and nanoparticles. Int J Nanomed 6:1463–1473.
65. Seil JT, Webster TJ. 2012. Antimicrobial applications of nanotechnology: methods and literature. Int J Nanomed 7:2767–2781.
66. Carter RR, Sun J, Jump RL. 2016. A survey and analysis of the American public's perceptions and knowledge about antibiotic resistance. Open Forum Infect Dis 3:ofw112.
67. Wolcott R, Costerton J, Raoult D, et al. 2013. The polymicrobial nature of biofilm infection. Clin Microbiol Infec 19:107–112.
68. Hall BB, Fitzgerald RH Jr., Rosenblatt JE. 1983. Anaerobic osteomyelitis. J Bone Joint Surg Am 65:30–35.